<p>Bright Minds Biosciences（纳斯达克股票代码：DRUG - 获取免费报告）的股票在 BTIG Research 发布给客户和投资者的研究报告中重申了 “买入” 评级，Benzinga 报道。他们目前对该股票的目标价格为 147.00 美元。BTIG Research 的目标价格意味着该股票相较于之前的收盘价有 109.70% 的潜在上涨空间。</p>
<ul>
<li>生物科技行业的边缘：2 只具有巨大潜力的股票</li>
</ul>
<p>其他几家券商也对 DRUG 发布了报告。Zacks Research 在 12 月 2 日的报告中将 Bright Minds Biosciences 的股票评级从 “强力买入” 下调至 “持有”。Wall Street Zen 在 3 月 21 日的研究报告中将 Bright Minds Biosciences 的股票评级从 “卖出” 上调至 “持有”。HC Wainwright 在 3 月 4 日的研究报告中将 Bright Minds Biosciences 的目标价格从 115.00 美元提升至 145.00 美元，并给予该公司 “买入” 评级。Robert W. Baird 在 2 月 13 日的报告中设定了 Bright Minds Biosciences 的目标价格为 126.00 美元。最后，Cantor Fitzgerald 在 12 月 1 日的研究报告中重申了对 Bright Minds Biosciences 的 “增持” 评级。五位投资分析师对该股票给予了买入评级，一位给予了持有评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，平均目标价格为 124.50 美元。</p>
<p><strong>查看我们关于 DRUG 的最新报告</strong></p>
<h2>Bright Minds Biosciences 股票表现</h2>
<ul>
<li>Bright Minds Biosciences 股票飙升近 1500%</li>
</ul>
<p>DRUG 在周一的开盘价为 70.10 美元。Bright Minds Biosciences 的年低为 23.17 美元，年高为 123.75 美元。该股票的市值为 6.8207 亿美元，市盈率为-36.32，贝塔值为-6.03。该公司的 50 日移动平均价格为 79.18 美元，200 日移动平均价格为 71.54 美元。</p>
<p>Bright Minds Biosciences（纳斯达克股票代码：DRUG - 获取免费报告）最后一次发布财报是在 2 月 12 日，周四。该公司报告每股收益（EPS）为-0.70 美元，超出市场共识预期的-0.98 美元，超出幅度为 0.28 美元。作为一个整体，股票研究分析师预测 Bright Minds Biosciences 在当前财政年度的每股收益将为-1.24 美元。</p>
<h2>对 Bright Minds Biosciences 的对冲基金看法</h2>
<p>几家机构投资者最近买入和卖出了该公司的股票。Virtu Financial LLC 在第四季度购买了 Bright Minds Biosciences 的新股份，价值约 226,000 美元。Invesco Ltd.在第四季度购买了 Bright Minds Biosciences 的新头寸，价值约 328,000 美元。Ikarian Capital LLC 在第四季度将其在 Bright Minds Biosciences 的持股增加了 933.1%。Ikarian Capital LLC 现在拥有 159,421 股该公司的股票，价值为 12,441,000 美元，此前在上个季度又购买了 143,990 股。Wellington Management Group LLP 在第四季度获得了 Bright Minds Biosciences 的新头寸，价值约 1,068,000 美元。最后，Millennium Management LLC 在第四季度将其在 Bright Minds Biosciences 的股份增加了 153.6%。Millennium Management LLC 现在拥有 194,437 股该公司的股票，价值 15,174,000 美元，此前在此期间又购买了 117,756 股。40.52% 的股票由机构投资者和对冲基金持有。</p>
<h2>Bright Minds Biosciences 公司简介</h2>
<p>（获取免费报告）</p>
<p>Bright Minds Biosciences Inc 在纳斯达克交易，股票代码为 DRUG，是一家临床阶段的生物技术公司，专注于开发用于心理健康和神经退行性疾病的新型小分子治疗药物。该公司的研究利用专有化学平台创建源自迷幻药结构的调节血清素和神经保护化合物。Bright Minds 旨在通过口服治疗解决重度抑郁症、创伤后应激障碍和阿尔茨海默病等疾病的未满足需求。</p>
<p>该公司的主要候选药物 BMB-101 是一种口服 5-HT2A 受体调节化合物，正在临床开发中，针对情绪和焦虑障碍。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Bright Minds Biosciences</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJVRw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJVRw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Bright Minds Biosciences 吗？</h2>
<p>在你考虑 Bright Minds Biosciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Bright Minds Biosciences 并不在名单上。</p>
<p>虽然 Bright Minds Biosciences 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

医疗业 ETF - Vanguard

标普生物技术 3 倍做多 - Direxion

DRUG

<p>BTIG Research 重申了对 Bright Minds Biosciences (NASDAQ:DRUG) 的 “买入” 评级，目标价格为 147.00 美元，暗示潜在上涨幅度为 109.70%。其他分析师的评级则各有不同，Zacks 将其评级下调至 “持有”，而 HC Wainwright 则将目标价上调至 145.00 美元。该股票开盘价为 70.10 美元，过去一年最高价为 123.75 美元。Bright Minds 专注于开发针对心理健康和神经退行性疾病的治疗药物，其主要候选药物正在针对情绪和焦虑障碍进行临床开发</p>

<p>Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report)'s stock had its &#34;buy&#34; rating reiterated by equities research analysts at BTIG Research in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $147.00 target price on the stock. BTIG Research's price target would indicate a potential upside of 109.70% from the stock's previous close.</p>
<div class="lb-trans"><p>Bright Minds Biosciences（纳斯达克股票代码：DRUG - 获取免费报告）的股票在 BTIG Research 发布给客户和投资者的研究报告中重申了 “买入” 评级，Benzinga 报道。他们目前对该股票的目标价格为 147.00 美元。BTIG Research 的目标价格意味着该股票相较于之前的收盘价有 109.70% 的潜在上涨空间。</p>
</div><ul>
<li>Biotechs on the Brink: 2 Stocks With Huge Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技行业的边缘：2 只具有巨大潜力的股票</li>
</ul>
</div><p>Several other brokerages have also issued reports on DRUG. Zacks Research lowered shares of Bright Minds Biosciences from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, December 2nd. Wall Street Zen raised shares of Bright Minds Biosciences from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, March 21st. HC Wainwright boosted their price target on shares of Bright Minds Biosciences from $115.00 to $145.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, March 4th. Robert W. Baird set a $126.00 price objective on shares of Bright Minds Biosciences in a report on Friday, February 13th. Finally, Cantor Fitzgerald reaffirmed an &#34;overweight&#34; rating on shares of Bright Minds Biosciences in a research report on Monday, December 1st. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $124.50.</p>
<div class="lb-trans"><p>其他几家券商也对 DRUG 发布了报告。Zacks Research 在 12 月 2 日的报告中将 Bright Minds Biosciences 的股票评级从 “强力买入” 下调至 “持有”。Wall Street Zen 在 3 月 21 日的研究报告中将 Bright Minds Biosciences 的股票评级从 “卖出” 上调至 “持有”。HC Wainwright 在 3 月 4 日的研究报告中将 Bright Minds Biosciences 的目标价格从 115.00 美元提升至 145.00 美元，并给予该公司 “买入” 评级。Robert W. Baird 在 2 月 13 日的报告中设定了 Bright Minds Biosciences 的目标价格为 126.00 美元。最后，Cantor Fitzgerald 在 12 月 1 日的研究报告中重申了对 Bright Minds Biosciences 的 “增持” 评级。五位投资分析师对该股票给予了买入评级，一位给予了持有评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，平均目标价格为 124.50 美元。</p>
</div><p><strong>View Our Latest Report on DRUG</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 DRUG 的最新报告</strong></p>
</div><h2>Bright Minds Biosciences Stock Performance</h2>
<div class="lb-trans"><h2>Bright Minds Biosciences 股票表现</h2>
</div><ul>
<li>Bright Minds Biosciences Stock Surges Almost 1,500%</li>
</ul>
<div class="lb-trans"><ul>
<li>Bright Minds Biosciences 股票飙升近 1500%</li>
</ul>
</div><p>DRUG opened at $70.10 on Monday. Bright Minds Biosciences has a one year low of $23.17 and a one year high of $123.75. The stock has a market capitalization of $682.07 million, a PE ratio of -36.32 and a beta of -6.03. The business's 50 day moving average price is $79.18 and its 200 day moving average price is $71.54.</p>
<div class="lb-trans"><p>DRUG 在周一的开盘价为 70.10 美元。Bright Minds Biosciences 的年低为 23.17 美元，年高为 123.75 美元。该股票的市值为 6.8207 亿美元，市盈率为-36.32，贝塔值为-6.03。该公司的 50 日移动平均价格为 79.18 美元，200 日移动平均价格为 71.54 美元。</p>
</div><p>Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) last posted its earnings results on Thursday, February 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.98) by $0.28. As a group, equities research analysts forecast that Bright Minds Biosciences will post -1.24 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Bright Minds Biosciences（纳斯达克股票代码：DRUG - 获取免费报告）最后一次发布财报是在 2 月 12 日，周四。该公司报告每股收益（EPS）为-0.70 美元，超出市场共识预期的-0.98 美元，超出幅度为 0.28 美元。作为一个整体，股票研究分析师预测 Bright Minds Biosciences 在当前财政年度的每股收益将为-1.24 美元。</p>
</div><h2>Hedge Funds Weigh In On Bright Minds Biosciences</h2>
<div class="lb-trans"><h2>对 Bright Minds Biosciences 的对冲基金看法</h2>
</div><p>Several institutional investors have recently bought and sold shares of the company. Virtu Financial LLC purchased a new stake in Bright Minds Biosciences during the fourth quarter worth about $226,000. Invesco Ltd. purchased a new position in shares of Bright Minds Biosciences in the fourth quarter valued at approximately $328,000. Ikarian Capital LLC grew its holdings in shares of Bright Minds Biosciences by 933.1% in the fourth quarter. Ikarian Capital LLC now owns 159,421 shares of the company's stock valued at $12,441,000 after purchasing an additional 143,990 shares in the last quarter. Wellington Management Group LLP acquired a new position in shares of Bright Minds Biosciences in the fourth quarter valued at approximately $1,068,000. Finally, Millennium Management LLC increased its stake in Bright Minds Biosciences by 153.6% during the 4th quarter. Millennium Management LLC now owns 194,437 shares of the company's stock worth $15,174,000 after buying an additional 117,756 shares during the period. 40.52% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家机构投资者最近买入和卖出了该公司的股票。Virtu Financial LLC 在第四季度购买了 Bright Minds Biosciences 的新股份，价值约 226,000 美元。Invesco Ltd.在第四季度购买了 Bright Minds Biosciences 的新头寸，价值约 328,000 美元。Ikarian Capital LLC 在第四季度将其在 Bright Minds Biosciences 的持股增加了 933.1%。Ikarian Capital LLC 现在拥有 159,421 股该公司的股票，价值为 12,441,000 美元，此前在上个季度又购买了 143,990 股。Wellington Management Group LLP 在第四季度获得了 Bright Minds Biosciences 的新头寸，价值约 1,068,000 美元。最后，Millennium Management LLC 在第四季度将其在 Bright Minds Biosciences 的股份增加了 153.6%。Millennium Management LLC 现在拥有 194,437 股该公司的股票，价值 15,174,000 美元，此前在此期间又购买了 117,756 股。40.52% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Bright Minds Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Bright Minds Biosciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.</p>
<div class="lb-trans"><p>Bright Minds Biosciences Inc 在纳斯达克交易，股票代码为 DRUG，是一家临床阶段的生物技术公司，专注于开发用于心理健康和神经退行性疾病的新型小分子治疗药物。该公司的研究利用专有化学平台创建源自迷幻药结构的调节血清素和神经保护化合物。Bright Minds 旨在通过口服治疗解决重度抑郁症、创伤后应激障碍和阿尔茨海默病等疾病的未满足需求。</p>
</div><p>The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.</p>
<div class="lb-trans"><p>该公司的主要候选药物 BMB-101 是一种口服 5-HT2A 受体调节化合物，正在临床开发中，针对情绪和焦虑障碍。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Bright Minds Biosciences</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Bright Minds Biosciences</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJVRw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=DRUG"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bright Minds Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Bright Minds Biosciences 吗？</h2>
</div><p>Before you consider Bright Minds Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Bright Minds Biosciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bright Minds Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Bright Minds Biosciences 并不在名单上。</p>
</div><p>While Bright Minds Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Bright Minds Biosciences 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Bright Minds Biosciences（NASDAQ:DRUG）被 BTIG Research 给予买入评级